241 related articles for article (PubMed ID: 22019238)
21. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation.
Tsujino K; Hirota S; Kotani Y; Kado T; Yoden E; Fujii O; Soejima T; Adachi S; Takada Y
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1100-5. PubMed ID: 16373082
[TBL] [Abstract][Full Text] [Related]
22. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
[TBL] [Abstract][Full Text] [Related]
23. Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement.
Lagrange JL; Thyss A; Caldani C; Héry M; Schneider M; Bensadoun JR
Bull Cancer; 1988; 75(8):801-6. PubMed ID: 2460169
[TBL] [Abstract][Full Text] [Related]
24. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
[TBL] [Abstract][Full Text] [Related]
25. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
Busia A; Laffranchi A; Viviani S; Bonfante V; Villani F
Anticancer Res; 2010 Oct; 30(10):4381-7. PubMed ID: 21036768
[TBL] [Abstract][Full Text] [Related]
26. Radiation pneumonitis in pediatric Hodgkin lymphoma patients receiving radiation therapy to the chest.
Lewis GD; Agrusa JE; Teh BS; Gramatges MM; Kothari V; Allen CE; Paulino AC
Pract Radiat Oncol; 2018; 8(5):e364-e368. PubMed ID: 29730281
[TBL] [Abstract][Full Text] [Related]
27. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
[TBL] [Abstract][Full Text] [Related]
28. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
29. Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy.
Piotrowski T; Matecka-Nowak M; Milecki P
Neoplasma; 2005; 52(1):56-62. PubMed ID: 15739028
[TBL] [Abstract][Full Text] [Related]
30. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
Lind PA; Marks LB; Jamieson TA; Carter DL; Vredenburgh JJ; Folz RJ; Prosnitz LR
Cancer; 2002 Jun; 94(11):2821-9. PubMed ID: 12115368
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
[TBL] [Abstract][Full Text] [Related]
32. Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.
Haberer S; Belin L; Le Scodan R; Kirova YM; Savignoni A; Stevens D; Moisson P; Decaudin D; Pierga JY; Reyal F; Campana F; Fourquet A; Bollet MA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e145-52. PubMed ID: 21605948
[TBL] [Abstract][Full Text] [Related]
33. Predictive models for pulmonary function changes after radiotherapy for breast cancer and lymphoma.
Sánchez-Nieto B; Goset KC; Caviedes I; Delgado IO; Córdova A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e257-64. PubMed ID: 21621341
[TBL] [Abstract][Full Text] [Related]
34. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM
Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171
[TBL] [Abstract][Full Text] [Related]
35. Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
Sibon D; Ertault M; Al Nawakil C; de Bazelaire C; Franchi P; Brière J; de Kerviler E; Beranger N; Thieblemont C; Brice P
Br J Haematol; 2011 Apr; 153(2):191-8. PubMed ID: 21385169
[TBL] [Abstract][Full Text] [Related]
36. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
37. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
Kim TH; Cho KH; Pyo HR; Lee JS; Han JY; Zo JI; Lee JM; Hong EK; Choi IJ; Park SY; Shin KH; Kim DY; Kim JY
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):995-1002. PubMed ID: 15990000
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the risk of solid tumor following Hodgkin's disease.
Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
[TBL] [Abstract][Full Text] [Related]
39. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer?
Taghian AG; Assaad SI; Niemierko A; Floyd SR; Powell SN
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):386-91. PubMed ID: 15890579
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury.
Cella L; Liuzzi R; D'Avino V; Conson M; Di Biase A; Picardi M; Pugliese N; Solla R; Salvatore M; Pacelli R
Acta Oncol; 2014 May; 53(5):613-9. PubMed ID: 24195693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
